ArticleThe Journal of veterinary medical science2025
Soy isoflavone yeast fermented extract inhibits contraction of rat ileal smooth muscle via opening of K
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects of soy isoflavone yeast fermented extract (soyF) and soy isoflavone yeast unfermented extract (soyN) on rat ileal smooth muscle contraction. SoyF and soyN inhibited carbachol (CCh)- or KCl-induced contraction in a concentration-dependent manner; however, these effects were stronger for CCh-induced contraction than that for KCl, and the relaxation effect was stronger for soyF than for soyN. SoyF-induced relaxation was attenuated by 4-aminopyridine (4-AP), a Kv channel inhibitor, and iberiotoxin (IbTX), a calcium-activated potassium channel (BK channel) inhibitor. This relaxation was also decreased by 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine (SQ22536) and 1H-[1, 2, 4]oxadiazolo[4,3-a] quinoxalin-1-one (ODQ). Moreover, simultaneous treatment involving SQ22536 with 4-AP or IbTX further restored soyF-induced inhibition compared with each single treatment, whereas simultaneous treatment with ODQ and 4-AP or IbTX did not restore soyF-induced inhibition. SoyF increased cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in ileal strips. In β-escin-permeabilized muscle, CCh, guanosine 5'-O(3-thiotriphosphate) (GTPγS), and phorbol-12,13-dibutyrate (PDBu)-enhanced Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.